5-Amino-1MQ for Health & Longevity

Evidence Review created on 09/05/2026 using AI4L / Opus 5

Also known as: 5-amino-1-methylquinolinium, 5-amino-1-methylquinolinium iodide, 5A1MQ, 5MQ

Motivation

5-Amino-1MQ is a small laboratory-made compound that switches off a single enzyme active in fat tissue, liver, and muscle. That enzyme consumes two things cells depend on: a coenzyme central to releasing energy from food, and the body’s main methyl donor, the chemical tag used to control which genes are switched on. Blocking the enzyme lets both build back up.

Interest began when researchers noticed the enzyme is unusually abundant in the fat tissue of people carrying excess weight, and that it becomes more active in muscle with age. Turning it down in mice reduced fat mass without reducing how much the animals ate, and restored strength in old animals. Those animal results moved the compound rapidly into wellness clinics and online research-chemical markets, well ahead of any human testing.

This review examines what is actually established about 5-Amino-1MQ: how it acts, what the animal and cell evidence shows and where that evidence stops, what the compound’s chemistry and its target suggest about harm, how it is sourced and dosed outside formal trials, and what markers the existing protocols track.

Benefits - Risks - Protocol - Conclusion

Grokipedia

5-Amino-1MQ

Consolidated encyclopedia entry covering the compound’s chemistry, enzyme target, animal evidence, and market status, useful as a fast orientation before reading the primary literature.

Examine

No Examine article exists for 5-Amino-1MQ. Examine covers dietary supplements and interventions with published human trial data; 5-Amino-1MQ is an unapproved research compound with no human trials, which is the likely reason it is not covered.

ConsumerLab

No ConsumerLab article exists for 5-Amino-1MQ. ConsumerLab tests retail dietary supplements and foods; 5-Amino-1MQ is sold as a research chemical rather than as a dietary supplement, which is the likely reason it falls outside their testing programme.

Systematic Reviews

No systematic reviews or meta-analyses for 5-Amino-1MQ were found on PubMed as of 05 September 2026.

The literature provides no systematic review or meta-analysis on either side of this intervention’s central trade-off: neither the claimed metabolic and muscular benefit nor the principal risk of unopposed methyl-donor and enzyme-product disruption is represented.

Mechanism of Action

5-Amino-1MQ inhibits nicotinamide N-methyltransferase. That enzyme transfers a methyl group from S-adenosylmethionine (SAM, the body’s principal methyl donor) onto nicotinamide (a form of vitamin B3), producing 1-methylnicotinamide (1-MNA) and consuming both. Nicotinamide is also the precursor for nicotinamide adenine dinucleotide (NAD+, the coenzyme cells use to release energy from food), so high enzyme activity drains the NAD+ and methylation pools at once. Inhibition therefore raises intracellular NAD+ and SAM and lowers 1-MNA, which in fat cells suppresses fat synthesis (Neelakantan et al., 2018) and raises oxygen consumption (Kraus et al., 2014).

A competing mechanistic reading argues the opposite. The product 1-MNA is not inert waste: it stabilises sirtuin 1 (SIRT1, a protein that senses cellular energy status and switches on stress-resistance genes) and, when supplied to mice, lowered liver and serum cholesterol (Hong et al., 2015). On that reading, removing 1-MNA could impair the pathways inhibition is meant to support.

Pharmacologically, 5-Amino-1MQ is membrane-permeable and does not inhibit related SAM-dependent methyltransferases or NAD+ salvage enzymes. Rodent work shows high systemic exposure and distribution into adipose tissue, muscle, and liver after subcutaneous dosing, with a half-life short enough that the original efficacy study dosed three times daily. Its permanent positive charge makes it a poor substrate for cytochrome P450 enzymes (the main drug-metabolising family) and points to renal clearance largely unchanged via organic cation transporters (OCT1 and OCT2, carriers that move charged compounds into liver and kidney cells), though this is not formally characterised. No human pharmacokinetic data exist.

Historical Context & Evolution

Nicotinamide N-methyltransferase was characterised in the 1950s as a liver enzyme whose job was thought to be disposal: methylating surplus vitamin B3 for excretion in urine. For half a century it was treated as a detoxification step and a convenient urinary marker of B3 status, not as a regulator of anything.

That framing changed in 2014, when a screen of fat tissue from mice with altered glucose transport found the enzyme to be the most strongly reciprocally regulated gene, and silencing it in fat and liver protected mice against diet-induced obesity by raising cellular energy expenditure (Kraus et al., 2014). A medicinal chemistry effort followed at the University of Texas Medical Branch and the University of Texas at San Antonio, testing methylquinolinium scaffolds for permeability and selectivity; 5-Amino-1MQ emerged as the lead compound and reversed diet-induced obesity in mice in 2018, then activated senescent muscle stem cells in aged mice in 2019.

The original disposal interpretation was not overturned so much as shown to be incomplete: the enzyme does clear excess vitamin B3, and its product carries its own signalling activity, which is why a 2015 study reached the opposite therapeutic conclusion from the same biology. Both readings remain live in the literature. What changed the compound’s trajectory was not new evidence but distribution: from about 2020 it appeared on research-chemical sites and in longevity clinics as oral capsules, and consumer use now runs far ahead of the published record.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: every efficacy finding for the compound itself comes from rodent studies and cultured-cell assays, and the single human dataset on the target enzyme is a genetic proxy rather than a clinical endpoint measured under treatment in more than one trial.

Medium 🟩 🟩

No benefit reaches Medium: there is no single human trial and no observational human cohort reporting any outcome after exposure to 5-Amino-1MQ.

Low 🟩

Lower Risk of Alcohol-Associated Fatty Liver

Human genetic data are the closest thing to a clinical result: among 612 heavy drinkers, carriers of variants that lower enzyme levels developed alcohol-associated fatty liver less often. This is a lifelong genetic proxy for mild inhibition, not the compound, and the cohort is small and retrospective.

Magnitude: Hazard ratio 0.67 (a hazard ratio below 1 means fewer events in the compared group; 95 percent confidence interval 0.49–0.90, the range the true value most likely occupies) for new alcohol-associated fatty liver.

Speculative 🟨

Reduction in Fat Mass Without Appetite Suppression

Blocking the enzyme raised fat-cell energy use and cut body weight and white fat in obese mice without lowering food intake. Evidence is rodent-only; no human body-composition data exist.

Improved Glucose Tolerance and Insulin Sensitivity

Twenty-eight days of dosing improved oral glucose tolerance and insulin sensitivity and suppressed high insulin in obese mice. No controlled human glucose data exist; the basis is animal work only.

Reduced Liver Fat ⚠️ Conflicted

Dosing reduced liver fat and normalised liver enzymes in obese mice. Yet the product it removes lowered liver fat in other mice. Net reading: the direction remains unresolved even in rodents.

Grip Strength and Muscle Regeneration in Aged Animals

In 22-to-24-month-old mice, inhibition raised grip strength by about 40 percent and improved regeneration after injury. All strength data come from mice; no human functional measures exist.

Lower Plasma Cholesterol ⚠️ Conflicted

Treated obese mice showed lower plasma total cholesterol. Conversely, supplying the removed product also lowered cholesterol. Net reading: both directions carry rodent support, so the lipid effect is unpredictable.

Lower Circulating Homocysteine

Fat tissue releases homocysteine (an amino acid linked to blood-vessel damage) through this enzyme, and inhibition cut that release in cultured tissue. The basis is cell and tissue work only.

Reduced Tissue Scarring in Kidney and Heart Models

Related inhibitors reduced kidney tubular ageing and scarring and heart stiffening in aged mice. Those used different molecules against the same enzyme; no human organ outcomes exist.

Slowed Tumour Growth

The compound shrank bladder tumours in mice and improved the effect of an immune-based cancer drug and slowed growth of cervical cancer cells. No human cancer data exist.

Benefit-Modifying Factors

Baseline enzyme burden: Fat-tissue enzyme expression rises with adiposity, so the animal effect sizes derive from obese models. Someone already lean has little of the target to suppress, and no data address response in that state.
Baseline biomarker levels: Urinary or plasma 1-methylnicotinamide indexes enzyme flux, and fasting insulin indexes the metabolic problem being targeted. Higher starting values plausibly leave more room to move; neither has been validated as a response predictor.
Genetic polymorphisms: Variants in SLC22A1 (the gene for organic cation transporter 1, which moves charged compounds into liver cells) plausibly alter exposure, and MTHFR variants (affecting folate-to-methyl conversion) alter the methyl pool the drug spares. Neither has been tested.
Sex-based differences: The obesity and muscle work used male mice almost exclusively; the heart study used aged females and a different inhibitor. No study compares sexes head-to-head, so any sex difference in response is entirely unknown.
Pre-existing health conditions: Insulin resistance, fatty liver, and age-related muscle loss are the states in which animal benefit appeared. Established liver or kidney disease alters clearance of charged compounds and could change exposure unpredictably.
Age-related considerations: Muscle enzyme expression rises with age, and the strength findings came from mice equivalent to older adults. That argues the older end of the target range has the most to gain, but also the most concurrent medication and the least renal reserve.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no human has been dosed in any published trial, so no adverse event has ever been recorded against a clinical endpoint, in one study or in several.

Medium 🟥 🟥

No risk reaches Medium: there is no single human trial and no observational human cohort reporting harms after exposure to 5-Amino-1MQ.

Low 🟥

Higher Baseline Liver Enzymes

In the human genetic dataset, people carrying variants that lower enzyme levels had higher alanine and aspartate aminotransferase before any heavy drinking. The exposure is lifelong genetic, not the compound, and the finding rests on a single retrospective cohort.

Magnitude: Both enzymes ran significantly higher in the genetically inhibited half of a 612-person cohort; the study reports the direction only and gives no effect size.

Speculative 🟨

Impaired Embryo Implantation

Blocking the enzyme in mice lowered embryo implantation rates, and women with repeated implantation failure show less of it in the womb lining. The basis is animal dosing and a human tissue association only.

Unknown Effect on Whole-Body Methylation Balance

The enzyme is a major consumer of the body’s main methyl donor; blocking it raises that pool, which could alter gene and histone methylation. No study has measured this in people.

Loss of 1-methylnicotinamide Signalling ⚠️ Conflicted

The removed product stabilises a cell-stress protein and improves liver lipids, yet also promotes fatty liver in alcohol models. Net reading: losing it is plausibly harmful in some tissues and protective in others.

Reduced Neuronal Self-Clearance and Shortened Lifespan on Enzyme Loss

Deleting the worm equivalent of this enzyme impaired neuronal self-clearance and shortened lifespan. The basis is invertebrate genetics rather than drug dosing, and relevance to time-limited human use is unknown.

Shared Chemical Class With Dopaminergic Neurotoxins

5-Amino-1MQ is a permanently charged methylated ring cation, the same broad class as pyridinium neurotoxins that damage dopamine neurons. No neurotoxicity has been reported for this compound; the concern is structural only.

Unverified Product Identity, Purity, and Dose

Consumer material is sold for research use with no regulator verifying identity, salt form, or content. No published analytical survey of marketed product exists; the basis is the absence of oversight rather than any measurement.

Nausea, Headache, and Sleep Disturbance

Users and clinics describe mild nausea, headache, thirst, and altered sleep in the first weeks. These are isolated unpublished reports with no denominator, no placebo comparison, and no confirmed product identity.

Absent Reproductive and Chronic Toxicology Data

No reproductive, developmental, carcinogenicity, or repeat-dose toxicology studies have been published for this compound. The rodent work ran weeks rather than lifetimes, so chronic toxicity and formal reproductive safety remain uncharacterised.

Risk-Modifying Factors

Genetic polymorphisms: MTHFR and COMT variants (COMT is catechol-O-methyltransferase, an enzyme that uses the same methyl donor to break down dopamine) sit on the methyl pool this compound spares, so methylation-sensitive individuals plausibly sit at the extremes.
Baseline biomarker levels: Elevated homocysteine, low vitamin B12 or folate, or raised liver enzymes at baseline mark the systems most exposed to a methyl-cycle perturbation, and leave no clean reference against which a later change could be read.
Sex-based differences: No published safety observation compares males and females, and no reproductive-toxicity study exists in either sex. Women of reproductive age therefore carry an entirely uncharacterised exposure risk.
Pre-existing health conditions: Reduced kidney function slows clearance of charged cations; hepatic impairment alters transporter handling. Any parkinsonian or neurodegenerative diagnosis intersects directly with the compound’s chemical-class concern.
Age-related considerations: Older adults at the upper end of the target range combine reduced renal reserve, more concurrent medication competing for cation transporters, and greater baseline neurological vulnerability, compounding every uncertainty above.

Key Interactions & Contraindications

Organic cation transporter substrates (metformin, dolutegravir, procainamide): Caution. Competition for the same renal and hepatic carriers could raise the co-administered drug’s exposure, with lactate accumulation the concern for metformin. Dosing is separated by four hours and the other drug monitored.
Organic cation transporter inhibitors (cimetidine, trimethoprim, ranolazine): Caution. These reduce renal secretion of charged cations and could raise 5-Amino-1MQ exposure unpredictably. Cimetidine is available over the counter, so this interaction is easily overlooked.
Over-the-counter high-dose nicotinamide or niacin: Caution. Both load the substrate the enzyme methylates, working directly against the intervention and raising flush and hepatic-strain risk with niacin. The products are separated in time, or one is omitted.
NAD+ precursor supplements (nicotinamide riboside, nicotinamide mononucleotide): Additive; monitor. Both raise the same coenzyme by different routes, so the consequence is an uncharacterised coenzyme overshoot of unknown tolerability. Mitigation is to introduce only one at a time.
Methyl-donor supplements (S-adenosylmethionine, trimethylglycine, methylfolate, methylcobalamin): Additive; monitor. All push the methyl pool in the same direction as enzyme inhibition, with over-methylation effects such as irritability and disturbed sleep the consequence. Homocysteine is tracked rather than the products combined without measurement.
Glucose- and weight-lowering agents (GLP-1 receptor agonists such as semaglutide, which mimic a gut hormone that curbs appetite; metformin; berberine): Additive; caution. Consequence is hypoglycaemia (blood sugar falling too low) risk from combined glucose lowering; mitigation is closer glucose monitoring and prescriber-led dose review.
Other interventions: Caloric restriction and resistance or endurance exercise were additive with enzyme inhibition in mice on fat mass and grip strength; severity is monitor only, the consequence being faster body-composition change. The compound is layered onto those, not substituted.

Populations who should avoid 5-Amino-1MQ:

Pregnancy and lactation, and anyone planning conception, given zero reproductive or developmental toxicology
Anyone under 18 years of age
Estimated glomerular filtration rate below 30 mL/min/1.73 m² (severe kidney impairment), given renal clearance of charged cations
Child-Pugh Class B or C liver disease (moderate to severe cirrhosis)
Parkinson disease or any other parkinsonian syndrome, and first-degree relatives of an affected person
Active malignancy or treatment within the last 12 months, since all cancer data are preclinical and none address safety alongside oncology treatment
Untreated vitamin B12 deficiency or homocystinuria (an inherited disorder in which homocysteine builds up), or baseline homocysteine above 15 µmol/L

Risk Mitigation Strategies

Baseline methyl-cycle panel: Homocysteine, vitamin B12, and folate are measured before the first dose and again at eight weeks. This detects the methylation-balance disturbance that is the principal mechanistic risk, and creates a personal reference point.
Low starting dose with slow escalation: Protocols typically open at 50 mg once daily for two weeks before any increase toward 100-150 mg. Slow escalation limits the nausea, headache, and sleep disruption reported in the first weeks.
Certificate of analysis before purchase: A batch certificate showing identity by mass spectrometry, purity of at least 98 percent by liquid chromatography, salt form, and heavy-metal results is the practical check against the unverified product identity risk.
Time-limited cycles: Protocols run 8-12 weeks on, then a minimum four-week interval off. Because no repeat-dose or carcinogenicity toxicology exists, bounded exposure limits the chronic-toxicity risk that lifetime dosing would carry.
Liver panel at baseline and week 8: Alanine aminotransferase and aspartate aminotransferase track the organ where the removed product’s own signalling role is most contested, and where the conflicted liver-fat evidence makes the net direction unpredictable.
No concurrent introduction of other unapproved compounds: Nothing else new is introduced for the duration of a cycle. Without that constraint any adverse effect is unattributable, which is the practical failure mode of combined research-chemical protocols.
Neurological self-monitoring: Any new resting tremor, slowed movement, reduced arm swing, or handwriting change prompts discontinuation. This addresses the structural-class concern shared with pyridinium neurotoxins.

Therapeutic Protocol

Standard clinic protocol: Longevity and weight-management clinics dispensing compounded material typically use 50-150 mg orally once daily for 8-12 weeks, most commonly 100 mg, with a smaller number using 2.5-5 mg subcutaneously.
Competing approach, allometric dosing: A second approach scales from the mouse efficacy dose of 20 mg/kg three times daily, which converts to far higher human exposures than clinics use. Neither approach rests on human pharmacokinetic data.
Competing approach, no pharmacological inhibition: The conventional alternative forgoes the compound entirely and uses approved agents for the same endpoints, accepting slower results in exchange for characterised safety. Neither route is established as the default.
Origin of each approach: The Watowich group at the University of Texas Medical Branch and its spin-out Ridgeline Therapeutics generated the underlying pharmacology; the fixed-dose oral consumer protocol originated with compounding-pharmacy and telehealth peptide clinics, not from trial data.
Best time of day: Morning dosing with food predominates. It aligns the compound’s short exposure window with daytime activity and moves it away from the altered sleep some users report when dosing later.
Half-life and dosing frequency: No human half-life exists. Rodent exposure was short enough that the foundational efficacy study dosed three times daily, which is the main argument that once-daily human protocols may underdose.
Single versus split dosing: Split dosing (for example 50 mg twice daily) is the more defensible reading of the rodent pharmacokinetics; once-daily dosing is used mainly for adherence. No comparison of the two exists in any species.
Genetic polymorphisms influencing dose: MTHFR and COMT variants shift methyl-pool handling and SLC22A1 variants shift cation transport, so pharmacogenetically informed protocols start at the low end. No dosing algorithm has been validated for any of these.
Sex-based differences: The dosing literature is almost entirely male rodent. No sex-specific dose adjustment can be justified from evidence, so protocols apply the same milligram dose to both sexes by default rather than by design.
Age-related considerations: Older adults, the group with the highest target enzyme expression, are typically started at 50 mg with a longer escalation interval because of reduced renal clearance and greater concurrent medication load.
Baseline biomarkers influencing response: Fasting insulin, body-fat percentage, and liver enzymes define the metabolic state in which animal benefit appeared, and protocols use them to decide whether a cycle is worth running at all.
Pre-existing conditions influencing response: Insulin resistance and fatty liver are the conditions the animal work modelled. Established kidney or liver disease alters exposure enough that protocols exclude rather than adjust for them.

Discontinuation & Cycling

Not intended as lifelong therapy: No repeat-dose or lifetime toxicology exists, so continuous indefinite use has no evidentiary basis. Protocols treat it as a bounded intervention rather than a chronic medication.
Withdrawal effects: None have been documented, and none are mechanistically expected, since the compound blocks an enzyme rather than acting on a receptor that could adapt or rebound.
Tapering: No taper is required. Enzyme inhibition is reversible and there is no receptor downregulation to unwind, so protocols stop the compound outright at the end of a cycle.
Cycling for efficacy: Cycling is used to limit unquantified chronic exposure rather than to preserve efficacy; no tolerance has been reported. The common pattern is 8-12 weeks on followed by at least four weeks off.
Expectation on stopping: Fat mass regained after discontinuation is the expected outcome if diet and training have not changed, because the animal effect tracked ongoing enzyme suppression rather than a durable reset.

Sourcing and Quality

Regulatory category: 5-Amino-1MQ is neither an approved medicine nor a lawful dietary supplement in the United States or European Union. Retail material is sold labelled “research use only”, which places all quality assurance on the buyer.
Compounding pharmacies: A prescription route through a 503A compounding pharmacy (one preparing medicines to individual prescriptions) is more controlled, since such facilities work to United States Pharmacopeia standards and document ingredient origin. No consumer brand carries third-party certification.
Certificate of analysis: A batch-specific certificate is the minimum check, showing identity by mass spectrometry or nuclear magnetic resonance, purity by high-performance liquid chromatography of at least 98 percent, plus heavy metals, microbial limits, and residual solvents.
Salt form and dose accuracy: Most material is the iodide salt, which is heavier than the free cation, so a labelled 50 mg can deliver appreciably less active compound. Whether a stated dose is salt-corrected is often left unspecified.
Formulation: Oral capsules dominate; sublingual and injectable preparations are also sold. Injectables carry sterility requirements that research-chemical suppliers are not equipped to meet, making the oral capsule the lower-risk format.

Practical Considerations

Time to effect: No human time course exists. The rodent studies ran 28 days for metabolic endpoints and eight weeks for strength, which is why clinic protocols set the first reassessment at 8-12 weeks rather than earlier.
Common pitfall, treating animal doses as human doses: Milligram-per-kilogram mouse doses do not convert directly to humans, and three-times-daily rodent dosing does not support once-daily human dosing. Both errors are widespread in consumer protocols.
Common pitfall, simultaneous combination: Adding it alongside NAD+ precursors, peptides, and glucose-lowering agents at once makes any benefit or harm unattributable, and multiplies the number of uncharacterised compounds in circulation simultaneously.
Regulatory status: Not approved by the United States Food and Drug Administration for any indication and not lawfully marketable as a dietary supplement. Use is entirely outside approved channels rather than off-label use of an approved medicine.
Cost and accessibility: Roughly 60-150 US dollars monthly for oral capsules, with no insurance coverage anywhere. Approved weight-lowering alternatives cost an order of magnitude more, so access is limited by willingness to buy outside regulated channels rather than by price.
Payer incentives: Institutional payers have a clear financial reason to prefer a cheap unapproved compound over approved agents costing an order of magnitude more, yet none will fund trials of a molecule that looks unpatentable, which helps explain the empty human record.

Interaction with Foundational Habits

Sleep: Direction is uncertain and reported as disruptive rather than beneficial. The proposed mechanism is raised cellular energy-coenzyme availability shifting daytime metabolic signalling. Practically, morning dosing is used, and anyone noting altered sleep onset in the first two weeks moves the dose earlier rather than increasing it.
Nutrition: Direct and potentiating with restricted energy intake. Enzyme inhibition combined with a switch to a low-fat diet normalised body composition in obese mice faster than the diet switch alone, and it also altered the gut bacterial profile. Adequate vitamin B12 and folate intake matters because the methyl cycle is directly engaged.
Exercise: Directly potentiating and the best-supported interaction. In aged mice, inhibition plus progressive weighted wheel running produced roughly 60 percent greater grip strength than sedentary controls, against about 40 percent for the compound alone and 20 percent for exercise alone. Resistance training is the practical partner; no timing effect around sessions has been studied.
Stress management: No direct interaction is documented and none is mechanistically predicted; the compound has no known effect on cortisol or the stress axis. The indirect consideration is that the methyl donor it spares is also used to break down stress hormones, so any effect on stress physiology would be indirect and remains untested.

Monitoring Protocol & Defining Success

Because no human trial has defined either efficacy or safety endpoints for this compound, monitoring is built around the systems the mechanism touches rather than around a validated response marker. Before a first cycle, a baseline set establishes the metabolic state the intervention targets and the methyl-cycle and organ parameters most exposed to disturbance: body composition, fasting insulin and glycated haemoglobin, a full lipid panel, liver enzymes, kidney function, homocysteine with vitamin B12 and folate, and grip strength as an objective functional anchor. Repeat testing at four weeks covers liver enzymes and homocysteine only, since those are the earliest plausible signals of harm. A full repeat at 12 weeks, at the end of a cycle, establishes whether anything moved. Thereafter, anyone continuing to cycle repeats the full panel every six months.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
Body fat percentage	10-20% (men), 18-28% (women)	Primary endpoint the animal work moved	Measured by DXA (dual-energy X-ray absorptiometry, a scan that separates fat, lean, and bone), or consistently by the same bioimpedance device
Fasting insulin	2-5 µIU/mL	Earliest marker of the insulin-sensitivity claim	8-12 hour fast; paired with fasting glucose to derive insulin resistance; conventional labs accept up to about 25 µIU/mL, far above the functional target
HOMA-IR	Below 1.5	Composite index of insulin resistance	HOMA-IR is the homeostatic model assessment of insulin resistance, calculated from fasting glucose and insulin, not ordered separately; the conventional insulin-resistance cut-off sits near 2.5
HbA1c	4.8-5.4%	Confirms any glucose change is sustained	HbA1c is glycated haemoglobin, a three-month average of blood sugar; conventional labs flag only above 5.7%
ALT and AST	Below 25 U/L (men), below 20 U/L (women)	Liver is where the evidence is most conflicted	ALT is alanine aminotransferase and AST is aspartate aminotransferase, enzymes released by liver injury; conventional upper limits near 40 U/L are far less sensitive
Homocysteine	Below 8 µmol/L	Direct readout of the methyl cycle the drug perturbs	Fasting sample; conventional labs accept up to 15 µmol/L, which is too permissive here
Vitamin B12 and folate	B12 above 500 pg/mL; folate 10-25 ng/mL	Methyl-cycle inputs that determine tolerance of the perturbation	Conventional B12 range starts near 200 pg/mL; testing precedes any supplementation, which would otherwise mask deficiency
ApoB	Below 80 mg/dL	Lipid effect is conflicted in both directions	ApoB is apolipoprotein B, one particle per artery-clogging lipoprotein; more informative than low-density lipoprotein cholesterol alone and does not require fasting; conventional labs flag only above about 130 mg/dL
eGFR and creatinine	eGFR above 90 mL/min/1.73 m²	Clearance route for a charged cation	eGFR is estimated glomerular filtration rate, a calculated measure of kidney filtering; conventional labs treat anything above 60 mL/min/1.73 m² as normal; creatine supplementation or hard exercise in the preceding 48 hours distorts the result
hs-CRP	Below 0.5 mg/L	Tracks the inflammatory component of the metabolic picture	hs-CRP is high-sensitivity C-reactive protein; conventional cardiovascular thresholds call anything below 3.0 mg/L low risk; a single raised value during any infection is uninterpretable and is repeated
Grip strength	No established target for this intervention; track change from the individual’s own baseline, with a 5% rise over 12 weeks as a working threshold	Objective functional anchor for the muscle claim	Same dynamometer, same arm, same time of day; best of three attempts
Plasma 1-methylnicotinamide	No established target; track direction of change from the individual’s own baseline, a fall indicating target engagement	Only available marker that the enzyme is actually inhibited	Specialist metabolomics assay, not on routine panels; interpretable only against the person’s own pre-dose value

Qualitative markers worth tracking alongside the laboratory panel:

Sleep onset latency and number of night awakenings, given the reported sleep disturbance
Daytime energy and perceived exertion during habitual training sessions
Appetite, which should be unchanged, since appetite suppression would point to something other than the intended mechanism
Gastrointestinal comfort in the first two weeks, the window in which nausea is reported
Any new tremor, movement slowing, or handwriting change, checked deliberately rather than incidentally

Emerging Research

No registered human trial: A ClinicalTrials.gov search on 2026-09-05 for 5-Amino-1MQ and for nicotinamide N-methyltransferase inhibitors returned no ongoing and no completed study of any such compound. No NCT identifier exists for this intervention, in any phase, anywhere in the registry.
Closest registered human data: NCT00519714, a completed randomised, double-blind, placebo-controlled Phase 2/3 trial of 195 participants, tested the enzyme’s product 1-methylnicotinamide for lipid effects in hypertriglyceridaemia (persistently high blood fats), addressing the metabolite rather than the inhibitor.
Kidney fibrosis and cellular ageing: Chanvillard et al., 2026 links the enzyme to tubular cell ageing in human chronic kidney disease biopsies and shows inhibition is protective in lab-grown kidney tissue and in mice, an entirely new indication direction.
Cardiac structure and function: Li et al., 2025 reports that a different inhibitor of the same enzyme improved cardiac strain and reduced ventricular fibrosis in aged female mice with heart failure with preserved ejection fraction, a stiff-heart syndrome.
Ischaemic limb function: Dong et al., 2025 found enzyme expression raised in muscle from patients with peripheral artery disease, and inhibition improved muscle strength and power in mice without improving blood flow.
Evidence that could weaken the case: Hong et al., 2015 shows the enzyme’s product is metabolically beneficial in liver, and Schmeisser and Parker, 2018 shows enzyme loss shortens invertebrate lifespan. Neither has been reconciled with the inhibition case.
Oncology direction, preclinical only: Yang et al., 2024 shows the compound shrank bladder tumours in mice and overcame resistance to an immune-based cancer drug, and inhibition slowed growth of cervical cancer cells. Both point the same way; neither has been tested in people.
Successor compounds: Puleo et al., 2026 argues newer inhibitors with better potency and oral availability, not 5-Amino-1MQ itself, are the ones likely to reach a first human trial, which would finally generate human safety data for the class.

Conclusion

5-Amino-1MQ blocks one enzyme that uses up two things cells need: the molecule that drives energy release, and the chemical tag that switches genes on and off. In mice, blocking it lowered fat mass without reducing food intake, improved blood sugar handling, cut liver fat, and raised grip strength in old animals, with the strength effect adding to what exercise achieved alone. Those results carried it into clinics.

The evidence base nearly stops there. The compound itself has never been given to a person: no published trial, no fertility or long-term safety work, no known human dose. The one human signal is indirect: people who naturally make less of this enzyme seem less prone to one form of fatty liver, yet showed higher liver readings to begin with. Most work showing benefit comes from one university group and its spin-out company, which hold patents on the compound class and so have a direct financial stake in its adoption; no professional society or advocacy body has taken a position, so no membership revenue shapes the picture. Two findings pull the other way: the substance the enzyme makes appears useful in liver, and removing the enzyme entirely shortened life in a simple animal.

For someone weighing this against approved options, almost every claim sits at the level of animal work, the safety picture is not unfavourable so much as blank, and the chemistry raises an unanswered structural question about a family of compounds toxic to the nerve cells that make dopamine.

Top - Benefits - Risks - Protocol

5-Amino-1MQ for Health & Longevity

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

High 🟩 🟩 🟩

Medium 🟩 🟩

Low 🟩

Lower Risk of Alcohol-Associated Fatty Liver

Speculative 🟨

Reduction in Fat Mass Without Appetite Suppression

Improved Glucose Tolerance and Insulin Sensitivity

Reduced Liver Fat ⚠️ Conflicted

Grip Strength and Muscle Regeneration in Aged Animals

Lower Plasma Cholesterol ⚠️ Conflicted

Lower Circulating Homocysteine

Reduced Tissue Scarring in Kidney and Heart Models

Slowed Tumour Growth

Benefit-Modifying Factors

Potential Risks & Side Effects

High 🟥 🟥 🟥

Medium 🟥 🟥

Low 🟥

Higher Baseline Liver Enzymes

Speculative 🟨

Impaired Embryo Implantation

Unknown Effect on Whole-Body Methylation Balance

Loss of 1-methylnicotinamide Signalling ⚠️ Conflicted

Reduced Neuronal Self-Clearance and Shortened Lifespan on Enzyme Loss

Shared Chemical Class With Dopaminergic Neurotoxins

Unverified Product Identity, Purity, and Dose

Nausea, Headache, and Sleep Disturbance

Absent Reproductive and Chronic Toxicology Data

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion